Innate Pharma to Host Event on IPH4502
Innate Pharma announced it will host an in-person and virtual event on November 18, 2026, to discuss its drug candidate IPH4502.
Stocks · News reference
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 14.29 percent increase over losses of $(0.28) per share from the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Innate Pharma announced it will host an in-person and virtual event on November 18, 2026, to discuss its drug candidate IPH4502.
Innate Pharma S.A. released its financial results for the nine months ended September 30, 2026, highlighting a strengthened cash position and progress in its clinical pipeline.
Innate Pharma reported that AstraZeneca has adjusted the expected timeline for the high-level data readout of the Phase 3 PACIFIC-9 clinical trial to the first half of 2027.
BTIG analyst Jeet Mukherjee reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $9 price target.
Innate Pharma (NASDAQ:IPHA) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on revenue of $9.10